Factor VIII/von Willebrand factor - Octapharma

Drug Profile

Factor VIII/von Willebrand factor - Octapharma

Alternative Names: Human factor VWF/FVIII concentrate; Wilate

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease
  • Phase III Surgical blood loss

Most Recent Events

  • 14 Nov 2016 Octapharma plans the INITIATE trial for Von Villebrand's disease in USA
  • 01 Nov 2016 Octapharma plans a phase III trial for severe Hemophilia A (In adolescescents, In adults, In the elderly, Treatment-experienced) in Bulgaria, Hungary, Poland, Romania, Russia, Serbia, and Ukraine (IV) (NCT02954575)
  • 17 Oct 2016 Factor VIII/von Willebrand factor licensed to Cardinal Health in Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top